On November 22, Meihua Bio announced that its wholly-owned subsidiary in Singapore intends to acquire key assets from Kyowa Hakko Bio Co., Ltd., a subsidiary of Kirin Holdings Company, Limited, for 10.5 billion yen (approximately 68.8 million USD). The acquisition includes food-grade amino acids, pharmaceutical-grade amino acids, and human milk oligosaccharides (HMO) businesses. Post-acquisition, Meihua Bio’s product pipeline will expand, and its industry chain will extend further into the high-value pharmaceutical-grade amino acid market. Additionally, this deal will establish new overseas business entities for Meihua Bio. (Sources: Meihua Bio, Pharmaceutical Raw Material Intelligence Bureau)
Sign Up to Receive China Updates Weekly Newsletter for FREE, HERE
Visit HPA-China’s Information Hub, HERE